You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創美藥業(02289.HK)2020年度歸母淨利潤升1%至4056萬元 末期息0.2元
格隆匯 03-27 01:23

格隆匯 3 月 27日丨創美藥業(02289.HK)公佈,截至2020年12月31日止年度,實現營業收入39.92億元(人民幣,下同),同比增長14.28%;歸屬於母公司股東的淨利潤4056萬元,同比增長1%;基本及稀釋每股收益0.3755元;擬派發末期股息每股0.2元(含税)。

主營業務收入於2020年間增加,較去年增長14.28%。原因如下:從各個公司貢獻收入的角度看,(i)全資子公司廣州創美藥業有限公司度過初步培育期,收入較去年同期明顯增加,貢獻營業收入同比增加2.155億元;(ii)全資子公司廣東創美藥業有限公司貢獻營業收入同比增加1.92億元;從產品貢獻收入的角度看,(i)由於疫情,帶動相關產品銷量增加;(ii)一級藥品品種的增加,今年一級品種銷售收入同比增長4.39億元,新增一級品種及今年升級為一級藥品品種的收入同比增長1.69億元。

集團的毛利率由截至2019年12月31日止年度的6.40%,下降至2020年12月31日止年度的6.02%。集團毛利率的下降主要是由於各類防疫產品出廠價格急速上升,中游及下游銷售價格受嚴格管控,導致成本上升,毛利率下降。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account